Skip to main content

Take our TMF Risk Score Survey today!

Trial Interactive News & Press

Friday, February 2, 2018 | 9:16 AM

ARCA Biopharma Selects TransPerfect's Trial Interactive

NEW YORK, February 2, 2018 TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that ARCA Biopharma has selected TransPerfect’s Trial Interactive eTMF solution as their enterprise platform for clinical trials.  


ARCA Biopharma is a Colorado-based biopharmaceutical company that focuses on developing genetically targeted therapies for cardiovascular diseases. They initially selected TransPerfect’s Trial Interactive eTMF to support a Phase 2 trial conducted across 50 sites, and will be using the multitenant, cloud-based solution to move all trials to a paperless environment.


The Trial Interactive e-clinical platform was designed by clinical professionals, for clinical professionals. It is used by biopharmaceutical organizations and CROs to streamline product development lifecycles in a secure 21 CFR Part 11-compliant environment. Trial Interactive speeds time to market by moving cumbersome traditional paper-based study start-up and TMF management to the cloud. Stakeholders have real-time access to documentation and transparency into workflows, which drastically reduces travel and shipping requirements associated with review and reconciliation.


“ARCA Biopharma is doing incredible work in the cardiovascular space, and their innovative approach to development is truly ground-breaking,” said Michael Smyth, General Manager, Life Sciences Solutions at TransPerfect. “By moving to a cloud-based solution for TMF management, ARCA is able to optimize trial decisions around key elements like site selection and performance, study start-up, and management of critical study data.”


“Our search for an eTMF solution required that we find a product that met DIA requirements and was designed and backed by people who truly understand the world of clinical trials,” said Eric Negrey, Senior Director of IT and Facilities at ARCA Biopharma. “The claims made by the Trial Interactive team during our evaluation process were proven overwhelmingly true; it’s easy to use, provides us with significant insight into TMF completeness, and reporting on key data is simple and comprehensive. Trial Interactive has without question improved ARCA’s ability to complete trials in the most efficient manner possible.”

About Trial Interactive

TransPerfect’s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect’s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact or +1 212.400.8848, or visit

About TransPerfect

TransPerfect is the world’s largest provider of language services and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at

Back to News